Wednesday 6-18-2014 Celgene Corp (CELG) $CELG opened at 160.48 hitting the high price of 161.20 and a day low of 158.83 with a total volume of 1,709,656. CELG had a previous close of 159.87 and has been seeing an average volume of 2,124,540.
Overall Average: 72% Buy
Recent stock forum discussions about CELG http://investorshangout.com/search?q=CELG&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - 2 hrs 57 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Better Stock Today Challenge: Celgene vs. Facebook
David Williamson and Jamal Carnette, The Motley Fool - Motley Fool - Wed Jun 18, 3:32PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Celgene takes on Facebook for this first... (full story)
Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs. (full story)
'Mad Money' Lightning Round: Sell, Sell, Sell Exxon Mobil
at The Street - Wed Jun 18, 5:00AM CDT
Cramer thinks Westlake Chemical is a winner but he's staying away from Smith & Wesson. (full story)
Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market
at The Street - Tue Jun 17, 7:31PM CDT
The market reacted correctly to the continued tensions in Iraq and the effect on oil, Cramer said. (full story)
How Much Does This Failure Hurt Celgene?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
Celgene 's Vidaza, which began facing U.S. generic competition in September of 2013, just can't seem to catch a break. First there was the generic competition -- which dropped sales by 27% year-over-year last quarter to $148 million. And more... (full story)
Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 12:40PM CDT
Celgene (CELG) presented data from a retrospective analysis of a phase III study on Pomalyst in the MM indication. (full story)
Up 32%: Time to Buy Bluebird Bio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 5:35PM CDT
Bluebird bio shareholders had a great day today, with the stock up 32% on some early stage data for LentiGlobin from its HGB-205 study examining the drug as a treatment for beta-thalassemia major. Two patients in the trial have gone off blood... (full story)
Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 5:10PM CDT
Celgene (CELG) has suffered a setback in its efforts to expand the label of Vidaza. (full story)
Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies. (full story)
2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news... (full story)
Better Stock Today Challenge: Energy Transfer Partners vs. Celgene
Joel South and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 12:00PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Energy Transfer Partners takes on Celgene... (full story)
Better Stock Today: Celgene vs. American Express
Tyler Riggs and David Williamson, The Motley Fool - Motley Fool - Sat Jun 14, 1:18PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Celgene takes on American Express for... (full story)
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ... (full story)
Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA
Business Wire - Sat Jun 14, 11:30AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that a retrospective analysis of MM-003, the Company's phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination, were presented at the 19th European Hematology Association annual congress. Pomalidomide is marketed as POMALYST(R) in the United States and IMNOVID(R) in the European Union. (full story)
Overall Average: 72% Buy
Recent stock forum discussions about CELG http://investorshangout.com/search?q=CELG&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - 2 hrs 57 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Better Stock Today Challenge: Celgene vs. Facebook
David Williamson and Jamal Carnette, The Motley Fool - Motley Fool - Wed Jun 18, 3:32PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Celgene takes on Facebook for this first... (full story)
Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs. (full story)
'Mad Money' Lightning Round: Sell, Sell, Sell Exxon Mobil
at The Street - Wed Jun 18, 5:00AM CDT
Cramer thinks Westlake Chemical is a winner but he's staying away from Smith & Wesson. (full story)
Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market
at The Street - Tue Jun 17, 7:31PM CDT
The market reacted correctly to the continued tensions in Iraq and the effect on oil, Cramer said. (full story)
How Much Does This Failure Hurt Celgene?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
Celgene 's Vidaza, which began facing U.S. generic competition in September of 2013, just can't seem to catch a break. First there was the generic competition -- which dropped sales by 27% year-over-year last quarter to $148 million. And more... (full story)
Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 12:40PM CDT
Celgene (CELG) presented data from a retrospective analysis of a phase III study on Pomalyst in the MM indication. (full story)
Up 32%: Time to Buy Bluebird Bio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 5:35PM CDT
Bluebird bio shareholders had a great day today, with the stock up 32% on some early stage data for LentiGlobin from its HGB-205 study examining the drug as a treatment for beta-thalassemia major. Two patients in the trial have gone off blood... (full story)
Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 5:10PM CDT
Celgene (CELG) has suffered a setback in its efforts to expand the label of Vidaza. (full story)
Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies. (full story)
2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news... (full story)
Better Stock Today Challenge: Energy Transfer Partners vs. Celgene
Joel South and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 12:00PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Energy Transfer Partners takes on Celgene... (full story)
Better Stock Today: Celgene vs. American Express
Tyler Riggs and David Williamson, The Motley Fool - Motley Fool - Sat Jun 14, 1:18PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Celgene takes on American Express for... (full story)
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ... (full story)
Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA
Business Wire - Sat Jun 14, 11:30AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that a retrospective analysis of MM-003, the Company's phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination, were presented at the 19th European Hematology Association annual congress. Pomalidomide is marketed as POMALYST(R) in the United States and IMNOVID(R) in the European Union. (full story)
